Skip to content

COOL-AMI EU Case Series Clinical Study

A Single-Center Case Series Clinical Study to Assess the Feasibility of Integrating Therapeutic Hypothermia Using the ZOLL IVTM System as an Adjunctive Therapy to Percutaneous Coronary Intervention in Patients With AMI

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02070913
Enrollment
352
Registered
2014-02-25
Start date
2013-09-30
Completion date
2019-04-16
Last updated
2020-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction

Keywords

Hypothermia, Acute Myocardial Infarction, Percutaneous Coronary Intervention, AMI, PCI, Therapeutic Hypothermia

Brief summary

A single-center, prospective case series clinical study consecutively enrolling up to 10 patients with expected duration of 12 months or less. The study objectives are to evaluate retention and the feasibility of integrating therapeutic hypothermia using the ZOLL IVTM System.

Interventions

None listed

Sponsors

ZOLL Circulation, Inc., USA
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* The patient is 18 years of age. * The patient must have symptoms consistent with AMI * MI with ST-segment elevation * The patient is eligible for PCI. * The expected timing of the treatment pathway for the patient will allow for at least 10 minutes of cooling with the IVTM System prior to PCI. * The patient or patient legal representative is willing to provide written, informed consent to participate in this clinical study.

Exclusion criteria

* The patient has had a previous myocardial infarction * The patient is experiencing cardiogenic shock * The patient is experiencing acute pulmonary edema. * The patient is presenting with cardiac arrest. * The patient is presenting with Killip risk stratification class II through IV. * The patient is presenting with Atrial Fibrillation. * The patient has a history of a prior large myocardial infarct or an infarct in the same segment that is currently affected. * The patient requires an immediate surgical or procedural intervention other than PCI * The patient has an aortic dissection. * The patient has hepatic failure. * The patient has end stage kidney disease. * The patient is febrile * Known chronic Congestive Heart Failure (CHF). * Known previous CABG. * Known recent stroke * Cardio-pulmonary decompensation that has occurred en route to the hospital * Contraindications to hypothermia * The patient has a known hypersensitivity or contraindication to aspirin, heparin, or sensitivity to contrast media, which cannot be adequately pre-medicated. * The patient has a known history of coagulopathy * The patient is known to be pregnant * The patient has a known hypersensitivity to antishivering medications. * Patient has a known history of severe hepatic or renal impairment. * The patient has an Inferior Vena Cava filter in place (IVC). * The patient has a life expectancy of less than 1 year * The patient has a known, unresolved history of drug use * The patient is currently enrolled another investigational drug or device trial

Design outcomes

Primary

MeasureTime frame
Time from hospital arrival to Percutaneous Coronary Intervention (PCI).24 hours
Time from hospital arrival to initiation of cooling.24 hours
Proportion of subjects achieving target temperature.24 hours

Secondary

MeasureTime frame
Proportion of those enrolled that complete the study protocol.24 hours

Countries

Czechia, Estonia, Germany, Hungary, Lithuania, Poland, Serbia, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026